Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 1,032.6% in January

Dermata Therapeutics, Inc. (NASDAQ:DRMAGet Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 295,600 shares, an increase of 1,032.6% from the December 31st total of 26,100 shares. Based on an average daily trading volume, of 918,800 shares, the short-interest ratio is presently 0.3 days. Currently, 10.5% of the company’s shares are sold short.

Dermata Therapeutics Price Performance

Shares of DRMA remained flat at $0.46 on Thursday. 120,749 shares of the company were exchanged, compared to its average volume of 2,704,773. Dermata Therapeutics has a twelve month low of $0.37 and a twelve month high of $5.62. The stock’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.92.

Dermata Therapeutics (NASDAQ:DRMAGet Free Report) last issued its earnings results on Thursday, November 9th. The company reported ($0.54) EPS for the quarter.

Institutional Investors Weigh In On Dermata Therapeutics

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC increased its stake in Dermata Therapeutics by 34.2% in the third quarter. Acadian Asset Management LLC now owns 75,538 shares of the company’s stock valued at $79,000 after purchasing an additional 19,253 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Dermata Therapeutics during the second quarter worth $29,000. Virtu Financial LLC bought a new stake in shares of Dermata Therapeutics during the second quarter worth $53,000. Renaissance Technologies LLC bought a new stake in shares of Dermata Therapeutics during the first quarter worth $34,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of Dermata Therapeutics during the fourth quarter worth $58,000. Institutional investors own 17.78% of the company’s stock.

Dermata Therapeutics Company Profile

(Get Free Report)

Dermata Therapeutics, Inc, a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

Featured Articles

Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.